PATENT CLAIM ANALYSIS

Application Number: 16050029
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-03
Patent Classification: ["424", "468000"]

Abstract:
A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.

Claim (Index 63):
The tablet as claimed in  claim 56 , wherein Compound 1 Form I is present in an amount of 30 to 70 wt % by weight of the tablet.

Metadata:
- Claim Count in Document: 107.0
- Percentile: 95.0
- Lexical Diversity: 1.61538
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15001036', '14542396', '13081750', '13942617', '15035969']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8065626380361435
- 35 USC 102 Novelty (BERT): 0.5876528169964168
- Combined Prediction Score: 0.7846716559321708
- Mean Citation Score: 509.374952
- Max Citation Score: 591.507
- Similarity Product: 400.1103222810029

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test